NRAS and neoplasm: Extended mutation analyses of additional tumour RAS loci (KRAS exons 3 and 4, and NRAS exons 2, 3 and 4) suggested that the efficacy benefit was further restricted to patients with tumours wild type at all screened loci (Douillard et al, 2013; Bokemeyer et al, 2015).